Bladder cancer is a common type of cancer that often begins in the urothelial cells lining the bladder, known as urothelial or transitional cell carcinoma (UC/TCC). Most bladder cancers are diagnosed at an early stage as non-muscle-invasive bladder cancer (NMIBC), which is highly treatable. Recurrence and progression to harder-to-treat stages, muscle-invasive (MIBC) and advanced/metastatic, is frequent. Immunotherapy has emerged as a highly successful tool in this field, with ample development across disease stages both as monotherapy and in combination with members of other key drug classes, including chemotherapy, targeted therapy, and toxin-conjugates.
Oncology Resource Group (ONCrg) is a team of expert analysts who rigorously evaluate the latest corporate reports, news, and data presentations to distill out important advances in complex therapeutic areas. Our comprehensive medical congress coverage, and continuous market surveillance put these advances into the context of an overarching competitive landscape in Bladder Cancer to help guide strategic and tactical commercial development decisions for market participants.